| Year |
Citation |
Score |
| 2023 |
Adamson RJ, Payne NC, Bartual SG, Mazitschek R, Bullock AN. Structural and biochemical characterization establishes a detailed understanding of KEAP1-CUL3 complex assembly. Free Radical Biology & Medicine. 204: 215-225. PMID 37156295 DOI: 10.1016/j.freeradbiomed.2023.04.021 |
0.38 |
|
| 2023 |
Ong HW, Liang Y, Richardson W, Lowry ER, Wells CI, Chen X, Silvestre M, Dempster K, Silvaroli JA, Smith JL, Wichterle H, Pabla NS, Ultanir SK, Bullock AN, Drewry DH, et al. Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective. Acs Chemical Neuroscience. PMID 37084253 DOI: 10.1021/acschemneuro.3c00135 |
0.343 |
|
| 2023 |
Ong HW, Liang Y, Richardson W, Lowry ER, Wells CI, Chen X, Silvestre M, Dempster K, Silvaroli JA, Smith JL, Wichterle H, Pabla NS, Ultanir SK, Bullock AN, Drewry DH, et al. A Potent and Selective CDKL5/GSK3 Chemical Probe is Neuroprotective. Biorxiv : the Preprint Server For Biology. PMID 36798313 DOI: 10.1101/2023.02.09.527935 |
0.333 |
|
| 2022 |
Chen Z, Zhang J, Murillo-de-Ozores AR, Castañeda-Bueno M, D'Amico F, Heilig R, Manning C, Sorrell FJ, D'Angiolella V, Fischer R, Mulder M, Gamba G, Alessi DR, Bullock AN. Sequence and structural variations determining the recruitment of WNK kinases to the KLHL3 E3 ligase. The Biochemical Journal. PMID 35179207 DOI: 10.1042/BCJ20220019 |
0.365 |
|
| 2021 |
Röhm S, Berger BT, Schröder M, Chatterjee D, Mathea S, Joerger AC, Pinkas DM, Bufton JC, Tjaden A, Kovooru L, Kudolo M, Pohl C, Bullock AN, Müller S, Laufer S, et al. Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe. Journal of Medicinal Chemistry. PMID 34506142 DOI: 10.1021/acs.jmedchem.1c00868 |
0.351 |
|
| 2021 |
Nonga OE, Lavogina D, Enkvist E, Kestav K, Chaikuad A, Dixon-Clarke SE, Bullock AN, Kopanchuk S, Ivan T, Ekambaram R, Viht K, Knapp S, Uri A. Crystal Structure-Guided Design of Bisubstrate Inhibitors and Photoluminescent Probes for Protein Kinases of the PIM Family. Molecules (Basel, Switzerland). 26. PMID 34299628 DOI: 10.3390/molecules26144353 |
0.333 |
|
| 2021 |
Szykowska A, Chen Y, Smith TB, Preger C, Yang J, Qian D, Mukhopadhyay SM, Wigren E, Neame SJ, Gräslund S, Persson H, Atkinson PJ, Di Daniel E, Mead E, Wang J, ... ... Bullock AN, et al. Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain. Structure (London, England : 1993). PMID 34233201 DOI: 10.1016/j.str.2021.06.010 |
0.328 |
|
| 2021 |
Williams E, Riesebos E, Kerr G, Bullock AN. ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex. Biomedicines. 9. PMID 33572801 DOI: 10.3390/biomedicines9020129 |
0.324 |
|
| 2020 |
Schröder M, Bullock AN, Fedorov O, Bracher F, Chaikuad A, Knapp S. DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity. Journal of Medicinal Chemistry. PMID 32787076 DOI: 10.1021/acs.jmedchem.0c00898 |
0.365 |
|
| 2020 |
Chen Z, Wasney GA, Picaud S, Filippakopoulos P, Vedadi M, D'Angiolella V, Bullock AN. Identification of a PGXPP degron motif in dishevelled and structural basis for its binding to the E3 ligase KLHL12. Open Biology. 10: 200041. PMID 32574548 DOI: 10.1098/rsob.200041 |
0.414 |
|
| 2020 |
Suebsuwong C, Dai B, Pinkas DM, Duddupudi AL, Li L, Bufton JC, Schlicher L, Gyrd-Hansen M, Hu M, Bullock AN, Degterev A, Cuny GD. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold. European Journal of Medicinal Chemistry. 200: 112417. PMID 32505849 DOI: 10.1016/J.Ejmech.2020.112417 |
0.408 |
|
| 2020 |
Hanke T, Wong JF, Berger BT, Abdi I, Berger LM, Tesch R, Tredup C, Bullock AN, Müller-Knapp S, Knapp S. A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5. Acs Chemical Biology. PMID 32176847 DOI: 10.1021/acschembio.0c00076 |
0.3 |
|
| 2019 |
Chaikuad A, Thangaratnarajah C, von Delft F, Bullock AN. Structural consequences of BMPR2 kinase domain mutations causing pulmonary arterial hypertension. Scientific Reports. 9: 18351. PMID 31797984 DOI: 10.1038/s41598-019-54830-7 |
0.36 |
|
| 2019 |
Salah E, Chatterjee D, Beltrami A, Tumber A, Preuss F, Canning P, Chaikuad A, Knaus P, Knapp S, Bullock AN, Mathea S. Lessons from LIMK1 enzymology and their impact on inhibitor design. The Biochemical Journal. PMID 31652302 DOI: 10.1042/BCJ20190517 |
0.378 |
|
| 2018 |
Hudson L, Mui J, Vázquez S, Carvalho DM, Williams E, Jones C, Bullock AN, Hoelder S. Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept. Journal of Medicinal Chemistry. PMID 30085668 DOI: 10.1021/Acs.Jmedchem.8B00782 |
0.353 |
|
| 2018 |
Hrdinka M, Schlicher L, Dai B, Pinkas DM, Bufton JC, Picaud S, Ward JA, Rogers C, Suebsuwong C, Nikhar S, Cuny GD, Huber KV, Filippakopoulos P, Bullock AN, Degterev A, et al. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. The Embo Journal. PMID 30026309 DOI: 10.15252/Embj.201899372 |
0.36 |
|
| 2018 |
Fulcher LJ, Bozatzi P, Tachie-Menson T, Wu KZL, Cummins TD, Bufton JC, Pinkas DM, Dunbar K, Shrestha S, Wood NT, Weidlich S, Macartney TJ, Varghese J, Gourlay R, Campbell DG, ... ... Bullock AN, et al. The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms. Science Signaling. 11. PMID 29789297 DOI: 10.1126/Scisignal.Aao2341 |
0.383 |
|
| 2018 |
Canning P, Park K, Gonçalves J, Li C, Howard CJ, Sharpe TD, Holt LJ, Pelletier L, Bullock AN, Leroux MR. CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary Function. Cell Reports. 22: 885-894. PMID 29420175 DOI: 10.1016/J.Celrep.2017.12.083 |
0.35 |
|
| 2018 |
Suebsuwong C, Pinkas DM, Ray SS, Bufton JC, Dai B, Bullock AN, Degterev A, Cuny GD. Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 29409752 DOI: 10.1016/J.Bmcl.2018.01.044 |
0.403 |
|
| 2017 |
Pinkas DM, Sanvitale CE, Bufton JC, Sorrell FJ, Solcan N, Chalk R, Doutch J, Bullock AN. Structural complexity in the KCTD family of Cullin3-dependent E3 ubiquitin ligases. The Biochemical Journal. 474: 3747-3761. PMID 28963344 DOI: 10.1042/BCJ20170527 |
0.317 |
|
| 2017 |
Williams E, Bullock AN. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone. PMID 28918311 DOI: 10.1016/j.bone.2017.09.004 |
0.379 |
|
| 2017 |
Dixon-Clarke SE, Shehata SN, Krojer T, Sharpe TD, von Delft F, Sakamoto K, Bullock AN. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16. The Biochemical Journal. 474: 699-713. PMID 28057719 DOI: 10.1042/BCJ20160941 |
0.44 |
|
| 2016 |
Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, ... ... Bullock AN, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nature Chemical Biology. PMID 27571479 DOI: 10.1038/Nchembio.2166 |
0.306 |
|
| 2016 |
Wang Z, Bian H, Bartual SG, Du W, Luo J, Zhao H, Zhang S, Mo C, Zhou Y, Xu Y, Tu ZC, Ren X, Lu X, Brekken RA, Yao L, ... Bullock AN, et al. Structure-Based Design of Tetrahydroisoquinoline-7-Carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. Journal of Medicinal Chemistry. PMID 27219676 DOI: 10.1021/acs.jmedchem.6b00140 |
0.338 |
|
| 2015 |
Dixon-Clarke SE, Elkins JM, Cheng SW, Morin GB, Bullock AN. Structures of the CDK12/CycK complex with AMP-PNP reveal a flexible C-terminal kinase extension important for ATP binding. Scientific Reports. 5: 17122. PMID 26597175 DOI: 10.1038/srep17122 |
0.402 |
|
| 2015 |
Bullock AN, Degterev A. Targeting RIPK1,2,3 to combat inflammation. Oncotarget. 6: 34057-8. PMID 26472031 DOI: 10.18632/Oncotarget.6106 |
0.339 |
|
| 2014 |
Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. Journal of Medicinal Chemistry. 57: 7900-15. PMID 25101911 DOI: 10.1021/Jm501177W |
0.378 |
|
| 2014 |
Canning P, Tan L, Chu K, Lee SW, Gray NS, Bullock AN. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. Journal of Molecular Biology. 426: 2457-70. PMID 24768818 DOI: 10.1016/J.Jmb.2014.04.014 |
0.422 |
|
| 2014 |
Schumacher FR, Sorrell FJ, Alessi DR, Bullock AN, Kurz T. Structural and biochemical characterization of the KLHL3-WNK kinase interaction important in blood pressure regulation. The Biochemical Journal. 460: 237-46. PMID 24641320 DOI: 10.1042/Bj20140153 |
0.44 |
|
| 2013 |
Linossi EM, Chandrashekaran IR, Kolesnik TB, Murphy JM, Webb AI, Willson TA, Kedzierski L, Bullock AN, Babon JJ, Norton RS, Nicola NA, Nicholson SE. Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. Plos One. 8: e70536. PMID 23990909 DOI: 10.1371/journal.pone.0070536 |
0.305 |
|
| 2013 |
Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. Acs Chemical Biology. 8: 2145-50. PMID 23899692 DOI: 10.1021/Cb400430T |
0.356 |
|
| 2013 |
Canning P, Cooper CD, Krojer T, Murray JW, Pike AC, Chaikuad A, Keates T, Thangaratnarajah C, Hojzan V, Ayinampudi V, Marsden BD, Gileadi O, Knapp S, von Delft F, Bullock AN. Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. The Journal of Biological Chemistry. 288: 7803-14. PMID 23349464 DOI: 10.1074/jbc.M112.437996 |
0.329 |
|
| 2012 |
Chaikuad A, Alfano I, Kerr G, Sanvitale CE, Boergermann JH, Triffitt JT, von Delft F, Knapp S, Knaus P, Bullock AN. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. The Journal of Biological Chemistry. 287: 36990-8. PMID 22977237 DOI: 10.1074/jbc.M112.365932 |
0.424 |
|
| 2012 |
Adams CJ, Pike AC, Maniam S, Sharpe TD, Coutts AS, Knapp S, La Thangue NB, Bullock AN. The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structure. Proceedings of the National Academy of Sciences of the United States of America. 109: 3778-83. PMID 22362889 DOI: 10.1073/pnas.1113731109 |
0.315 |
|
| 2012 |
Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S, Bracher F. 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. Journal of Medicinal Chemistry. 55: 403-13. PMID 22136433 DOI: 10.1021/jm201286z |
0.389 |
|
| 2011 |
Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D, Trappe J, Rauch U, Bracher F, Knapp S. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chemistry & Biology. 18: 67-76. PMID 21276940 DOI: 10.1016/J.Chembiol.2010.11.009 |
0.404 |
|
| 2011 |
Zadjali F, Pike AC, Vesterlund M, Sun J, Wu C, Li SS, Rönnstrand L, Knapp S, Bullock AN, Flores-Morales A. Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. The Journal of Biological Chemistry. 286: 480-90. PMID 21030588 DOI: 10.1074/jbc.M110.173526 |
0.313 |
|
| 2010 |
Filippakopoulos P, Low A, Sharpe TD, Uppenberg J, Yao S, Kuang Z, Savitsky P, Lewis RS, Nicholson SE, Norton RS, Bullock AN. Structural basis for Par-4 recognition by the SPRY domain- and SOCS box-containing proteins SPSB1, SPSB2, and SPSB4. Journal of Molecular Biology. 401: 389-402. PMID 20561531 DOI: 10.1016/j.jmb.2010.06.017 |
0.385 |
|
| 2010 |
López-Ramos M, Prudent R, Moucadel V, Sautel CF, Barette C, Lafanechère L, Mouawad L, Grierson D, Schmidt F, Florent JC, Filippakopoulos P, Bullock AN, Knapp S, Reiser JB, Cochet C. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 3171-85. PMID 20400536 DOI: 10.1096/Fj.09-143743 |
0.362 |
|
| 2009 |
Bullock AN, Russo S, Amos A, Pagano N, Bregman H, Debreczeni JE, Lee WH, von Delft F, Meggers E, Knapp S. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. Plos One. 4: e7112. PMID 19841674 DOI: 10.1371/Journal.Pone.0007112 |
0.378 |
|
| 2009 |
Akué-Gédu R, Rossignol E, Azzaro S, Knapp S, Filippakopoulos P, Bullock AN, Bain J, Cohen P, Prudhomme M, Anizon F, Moreau P. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. Journal of Medicinal Chemistry. 52: 6369-81. PMID 19788246 DOI: 10.1021/Jm901018F |
0.359 |
|
| 2009 |
Bullock AN, Das S, Debreczeni JE, Rellos P, Fedorov O, Niesen FH, Guo K, Papagrigoriou E, Amos AL, Cho S, Turk BE, Ghosh G, Knapp S. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure (London, England : 1993). 17: 352-62. PMID 19278650 DOI: 10.1016/J.Str.2008.12.023 |
0.383 |
|
| 2008 |
Baumli S, Lolli G, Lowe ED, Troiani S, Rusconi L, Bullock AN, Debreczeni JE, Knapp S, Johnson LN. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. The Embo Journal. 27: 1907-18. PMID 18566585 DOI: 10.1038/Emboj.2008.121 |
0.302 |
|
| 2007 |
Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America. 104: 20523-8. PMID 18077363 DOI: 10.1073/pnas.0708800104 |
0.357 |
|
| 2007 |
Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z, Knapp S. Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure (London, England : 1993). 15: 1493-504. PMID 17997974 DOI: 10.1016/j.str.2007.09.016 |
0.346 |
|
| 2007 |
Pogacic V, Bullock AN, Fedorov O, Filippakopoulos P, Gasser C, Biondi A, Meyer-Monard S, Knapp S, Schwaller J. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Research. 67: 6916-24. PMID 17638903 DOI: 10.1158/0008-5472.CAN-07-0320 |
0.36 |
|
| 2006 |
Bullock AN, Debreczeni JE, Edwards AM, Sundström M, Knapp S. Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proceedings of the National Academy of Sciences of the United States of America. 103: 7637-42. PMID 16675548 DOI: 10.1073/pnas.0601638103 |
0.363 |
|
| 2005 |
Bullock AN, Debreczeni JE, Fedorov OY, Nelson A, Marsden BD, Knapp S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. Journal of Medicinal Chemistry. 48: 7604-14. PMID 16302800 DOI: 10.1021/Jm0504858 |
0.41 |
|
| 2005 |
Bullock AN, Debreczeni J, Amos AL, Knapp S, Turk BE. Structure and substrate specificity of the Pim-1 kinase. The Journal of Biological Chemistry. 280: 41675-82. PMID 16227208 DOI: 10.1074/jbc.M510711200 |
0.395 |
|
| Show low-probability matches. |